{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:56:45Z","timestamp":1793303805114,"version":"4.5.0"},"reference-count":155,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":1053,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Intensive Care"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1186\/s13613-023-01146-5","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T13:01:34Z","timestamp":1686834094000},"page":"52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence"],"prefix":"10.1016","volume":"13","author":[{"given":"Pierluigi","family":"Viale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian E.","family":"Sandrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Maria","family":"Rossolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Lodise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1186\/s13613-023-01146-5_bb0010","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1097\/CCM.0b013e31828a674a","article-title":"Validation of predictors of adverse outcomes in hospital-acquired pneumonia in the ICU","volume":"41","author":"Esperatti","year":"2013","journal-title":"Crit Care Med"},{"key":"10.1186\/s13613-023-01146-5_bb0015","doi-asserted-by":"crossref","first-page":"ofx76","DOI":"10.1093\/ofid\/ofx176","article-title":"Prevalence of carbapenem-resistant Gram-negative infections in the United States predominated by Acinetobacter baumannii and Pseudomonas aeruginosa","volume":"4","author":"Cai","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0020","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s44197-022-00069-x","article-title":"Multinational prospective cohort study of mortality risk factors in 198 ICUs of 12 Latin American countries over 24 years: the effects of healthcare-associated infections","volume":"12","author":"Rosenthal","year":"2022","journal-title":"J Epidemiol Glob Health"},{"key":"10.1186\/s13613-023-01146-5_bb0025","doi-asserted-by":"crossref","unstructured":"Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, et al.; National Institutes of Health Antimicrobial Resistance Outcomes Research Initiative (NIH\u2013ARORI). Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis. 2018;67:1803\u201314.","DOI":"10.1093\/cid\/ciy378"},{"key":"10.1186\/s13613-023-01146-5_bb0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjms.2018.11.009","article-title":"Impact of delayed appropriate antibiotic therapy on patient outcomes by antibiotic resistance status from serious Gram-negative bacterial infections","volume":"357","author":"Bonine","year":"2019","journal-title":"Am J Med Sci"},{"key":"10.1186\/s13613-023-01146-5_bb0035","doi-asserted-by":"crossref","first-page":"ofz194","DOI":"10.1093\/ofid\/ofz194","article-title":"Antimicrobial resistance or delayed appropriate therapy\u2014does one influence outcomes more than the other among patients with serious infections due to carbapenem-resistant versus carbapenem-susceptible Enterobacteriaceae?","volume":"6","author":"Lodise","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0040","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s13054-021-03787-z","article-title":"Timing of antibiotic therapy in the ICU","volume":"25","author":"Kollef","year":"2021","journal-title":"Crit Care"},{"key":"10.1186\/s13613-023-01146-5_bb0045","doi-asserted-by":"crossref","first-page":"dlac089","DOI":"10.1093\/jacamr\/dlac089","article-title":"Early appropriate diagnostics and treatment of MDR Gram-negative infections","volume":"4","author":"Bassetti","year":"2022","journal-title":"JAC Antimicrob Resist."},{"key":"10.1186\/s13613-023-01146-5_bb0050","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jinf.2016.11.008","article-title":"Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance","volume":"74","author":"Fern\u00e1ndez-Barat","year":"2017","journal-title":"J Infect"},{"key":"10.1186\/s13613-023-01146-5_bb0055","first-page":"385","article-title":"Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug-resistant\/extensively drug-resistant\/pandrug-resistant bacteria","volume":"24","author":"Bassetti","year":"2018","journal-title":"Curr Opin Crit Care"},{"key":"10.1186\/s13613-023-01146-5_bb0060","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1055\/s-0039-1696662","article-title":"Difficult-to-treat antibiotic-resistant Gram-negative pathogens in the intensive care unit: epidemiology, outcomes, and treatment","volume":"40","author":"Strich","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1186\/s13613-023-01146-5_bb0065","doi-asserted-by":"crossref","unstructured":"Vincent JL, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC, et al.; EPIC III Investigators. Prevalence and outcomes of infection among patients in intensive care units in 2017. JAMA. 2020;323:1478\u201387.","DOI":"10.1001\/jama.2020.2717"},{"key":"10.1186\/s13613-023-01146-5_bb0070","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1080\/14787210.2021.1859369","article-title":"New perspectives in the antibiotic treatment of mechanically ventilated patients with infections from Gram-negatives","volume":"19","author":"Karvouniaris","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1186\/s13613-023-01146-5_bb0075","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s13054-021-03736-w","article-title":"Initial antimicrobial management of sepsis","volume":"25","author":"Niederman","year":"2021","journal-title":"Crit Care"},{"key":"10.1186\/s13613-023-01146-5_bb0080","doi-asserted-by":"crossref","unstructured":"Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al.; WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18:318\u201327.","DOI":"10.1016\/S1473-3099(17)30753-3"},{"key":"10.1186\/s13613-023-01146-5_bb0085","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1128\/AAC.01405-16","article-title":"Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa","volume":"60","author":"Ito","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-023-01146-5_bb0090","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ejmech.2018.06.014","article-title":"Cefiderocol (S-649266), a new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: structure activity relationship","volume":"155","author":"Aoki","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1186\/s13613-023-01146-5_bb0095","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1128\/AAC.03098-15","article-title":"Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases","volume":"60","author":"Ito-Horiyama","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-023-01146-5_bb0100","first-page":"e01454","article-title":"In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria","volume":"62","author":"Ito","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-023-01146-5_bb0105","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1093\/jac\/dky317","article-title":"Stability and low induction propensity of cefiderocol against chromosomal AmpC \u03b2-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae (Erratum in J Antimicrob Chemother. 2019;74:539)","volume":"73","author":"Ito","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1186\/s13613-023-01146-5_bb0110","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00877-21","article-title":"Contribution of PER-type and NDM-type \u03b2-lactamases to cefiderocol resistance in Acinetobacter baumannii","volume":"65","author":"Poirel","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-023-01146-5_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010334","article-title":"Widespread emergence of OmpK36 loop 3 insertions among multidrug-resistant clones of Klebsiella pneumoniae","volume":"18","author":"David","year":"2022","journal-title":"PLoS Pathog"},{"issue":"Suppl. 7","key":"10.1186\/s13613-023-01146-5_bb0120","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1093\/cid\/ciz826","article-title":"Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin","volume":"69","author":"Sato","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0125","unstructured":"Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 32nd ed. CLSI Supplement M100. Wayne, PA: 2022."},{"key":"10.1186\/s13613-023-01146-5_bb0130","unstructured":"Food and Drug Administration. FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria. Cefiderocol injection. 2021. https:\/\/www.fda.gov\/drugs\/development-resources\/cefiderocol-injection. Accessed 23 Sept 2022."},{"key":"10.1186\/s13613-023-01146-5_bb0135","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 13.0, 2023. http:\/\/www.eucast.org."},{"key":"10.1186\/s13613-023-01146-5_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2020.115012","article-title":"In vitro activity of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacilli isolated from patients in Canadian intensive care units","volume":"97","author":"Golden","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0145","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01990-21","article-title":"In vitro susceptibility of Gram-negative pathogens to cefiderocol in five consecutive annual multinational SIDERO-WT surveillance studies, 2014 to 2019","volume":"66","author":"Karlowsky","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 1","key":"10.1186\/s13613-023-01146-5_bb0150","doi-asserted-by":"crossref","first-page":"S625","DOI":"10.1093\/ofid\/ofab466.1260","article-title":"In vitro and in vivo antimicrobial activity of cefiderocol and comparators against Achromobacter spp","volume":"8","author":"Nakai","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1186\/s13613-023-01146-5_bb0155","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02712-21","article-title":"In vitro activity of cefiderocol against U.S. and European Gram-negative clinical isolates collected in 2020 as part of the SENTRY Antimicrobial Surveillance Program","volume":"10","author":"Shortridge","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1186\/s13613-023-01146-5_bb0160","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.diagmicrobio.2019.03.003","article-title":"Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth","volume":"94","author":"Hackel","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0165","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Guidance document on broth microdilution testing of cefiderocol BMD. 2020. www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Guidance:documents\/Cefiderocol_MIC_testing_EUCAST_guidance:document_201217.pdf"},{"key":"10.1186\/s13613-023-01146-5_bb0170","unstructured":"Marchetti P, Sanchez C, Echegorry M, Olivieri L, Ramirez MS, Faccone D, et al. Comparison of iron-depleted (ID) versus cation-adjusted Mueller-Hinton broth (CAMHB) media for cefiderocol susceptibility among carbapenemase-producing Enterobacterales (CPEs). Presented at 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), Copenhagen, Denmark. 15\u201318 April 2023; P0388."},{"key":"10.1186\/s13613-023-01146-5_bb0175","doi-asserted-by":"crossref","unstructured":"Devoos L, Biguenet A, Rousselot J, Bour M, Pl\u00e9siat P, Fournier D, et al. Performance of discs, sensititre EUMDROXF microplates and MTS gradient strips for the determination of the susceptibility of multidrug-resistant Pseudomonas aeruginosa to cefiderocol. Clin Microbiol Infect. 2023;29(5): 652.e1-652.e8. https:\/\/doi.org\/10.1016\/j.cmi.2022.12.021.","DOI":"10.1016\/j.cmi.2022.12.021"},{"key":"10.1186\/s13613-023-01146-5_bb0180","doi-asserted-by":"crossref","first-page":"1156.e1","DOI":"10.1016\/j.cmi.2022.04.013","article-title":"Comparison of disk diffusion, MIC test strip and broth microdilution methods for cefiderocol susceptibility testing on carbapenem-resistant Enterobacterales","volume":"28","author":"Bonnin","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1186\/s13613-023-01146-5_bb0185","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/antibiotics12030614","article-title":"Comparison of broth microdilution, disk diffusion and strip test methods for cefiderocol antimicrobial susceptibility testing on KPC-producing Klebsiella pneumoniae","volume":"12","author":"Bovo","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1186\/s13613-023-01146-5_bb0190","unstructured":"European Committee on Antimicrobial Susceptibility Testing. EUCAST warnings concerning antimicrobial susceptibility testing products or procedures. https:\/\/www.eucast.org\/ast-of-bacteria\/warnings. Accessed 14 Apr 2023."},{"key":"10.1186\/s13613-023-01146-5_bb0195","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1093\/jac\/dkac080","article-title":"Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing","volume":"77","author":"Matuschek","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1186\/s13613-023-01146-5_bb0200","unstructured":"Asensio Gallego S, Lopez Cerero L, Portillo Calderon I, Delgado Valverde M, Pascual A. Difficulties with cefiderocol susceptibility testing: assessment of commercial available methods with carbapenem resistant Gram-negative bacteria. Presented at 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), Copenhagen, Denmark. 15\u201318 April 2023; P0327."},{"key":"10.1186\/s13613-023-01146-5_bb0205","unstructured":"Dortet L, Niccolai C, Pfennigwerth N, Frisch S, Gonzalez C, Antonelli A, et al. Performance evaluation of the UMIC cefiderocol to determine MIC in Gram-negative bacteria. Presented at 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), Copenhagen, Denmark. 15\u201318 April 2023; O0964."},{"key":"10.1186\/s13613-023-01146-5_bb0210","unstructured":"Merino Garcia P, Barrio B, Culebras E, Rios E, Delgado-Iribarren A, Rodriguez-Avial I. In vitro activity of cefiderocol against carbapenem-resistant Gram-negative bacilli: comparative evaluation of broth microdilution, agar dilution prepared with iron depleted Mueller-Hinton broth, disk diffusion and UMIC Cefiderocol\u00ae. Presented at 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), Copenhagen, Denmark. 15\u201318 April 2023; P0352."},{"key":"10.1186\/s13613-023-01146-5_bb0215","unstructured":"Mezcord V, Wong O, Lopez C, Georgeos N, Fua V, Ozuna A, et al. Comparison of methods to determine Acinetobacter cefiderocol (CFD) susceptibility: are the results comparable between the different assays? Presented at 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), Copenhagen, Denmark. 15\u201318 April 2023; P0380."},{"key":"10.1186\/s13613-023-01146-5_bb0220","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3390\/antibiotics12030604","article-title":"Disc diffusion and ComASP\u00ae cefiderocol microdilution panel to overcome the challenge of cefiderocol susceptibility testing in clinical laboratory routine","volume":"12","author":"Bianco","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1186\/s13613-023-01146-5_bb0225","doi-asserted-by":"crossref","first-page":"e02163","DOI":"10.1128\/AAC.02163-17","article-title":"Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for Gram-negative bacteria, in healthy subjects","volume":"62","author":"Saisho","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-023-01146-5_bb0230","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.clinthera.2019.07.006","article-title":"Effect of cefiderocol, a siderophore cephalosporin, on QT\/QTc interval in healthy adult subjects","volume":"41","author":"Sanabria","year":"2019","journal-title":"Clin Ther"},{"key":"10.1186\/s13613-023-01146-5_bb0235","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1093\/jac\/dkz123","article-title":"Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects","volume":"74","author":"Katsube","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1186\/s13613-023-01146-5_bb0240","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/jcph.841","article-title":"Cefiderocol, a siderophore cephalosporin for Gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment","volume":"57","author":"Katsube","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1186\/s13613-023-01146-5_bb0245","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/jcph.1386","article-title":"Metabolism, excretion, and pharmacokinetics of [14 C]-cefiderocol (S-649266), a siderophore cephalosporin, in healthy subjects following intravenous administration","volume":"59","author":"Miyazaki","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"10.1186\/s13613-023-01146-5_bb0250","unstructured":"Fetroja. Cefiderocol for injection for intravenous use. Prescribing Information. Shionogi Inc., Florham Park, NJ 07932, USA. 2021."},{"key":"10.1186\/s13613-023-01146-5_bb0255","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00228-018-2458-9","article-title":"Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters","volume":"74","author":"Katsube","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1186\/s13613-023-01146-5_bb0260","unstructured":"Fetcroja. Cefiderocol (1 g powder for concentrate for solution for infusion). Summary of Product Characteristics. Shionogi B.V., 151 Kingsfordweg, 1043GR Amsterdam, The Netherlands. 2020."},{"key":"10.1186\/s13613-023-01146-5_bb0265","unstructured":"Llopis B, Bleibtreu A, Jacquet P, Selves A, Rohaut B, Junot H, et al. Pharmacokinetic study of cefiderocol in intensive care unit patients. ECCMID 2020. Abstract 9857. https:\/\/www.escmid.org\/guidelines_publications\/eccmid_2020_abstract_book. Accessed 23 Sep 2022."},{"key":"10.1186\/s13613-023-01146-5_bb0270","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3390\/antibiotics10060649","article-title":"Cefiderocol in critically ill patients with multi-drug resistant pathogens: real-life data on pharmacokinetics and microbiological surveillance (Erratum in: Antibiotics (Basel). 2021;10:1230)","volume":"10","author":"K\u00f6nig","year":"2021","journal-title":"Antibiotics (Basel)."},{"key":"10.1186\/s13613-023-01146-5_bb0275","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1093\/jac\/dkab280","article-title":"Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia (Erratum in: J Antimicrob Chemother. 2021; 76:3069)","volume":"76","author":"Katsube","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1186\/s13613-023-01146-5_bb0280","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s40262-021-01086-y","article-title":"Pharmacokinetics, pharmacodynamics, and dose optimization of cefiderocol during continuous renal replacement therapy (Erratum in: Clin Pharmacokinet. 2022;61:1069)","volume":"61","author":"Wenzler","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1186\/s13613-023-01146-5_bb0285","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.2703","article-title":"Cefiderocol dosing for patients receiving continuous renal replacement therapy","author":"Wei","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl2","key":"10.1186\/s13613-023-01146-5_bb0290","article-title":"Cefiderocol is not sequestered in an ex vivo extracorporeal membrane oxygenation (ECMO) circuit","volume":"9","author":"Berry","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0295","article-title":"Pharmacokinetics of cefiderocol during extracorporeal membrane oxygenation: a case report","volume":"28","author":"Riera","year":"2023","journal-title":"Perfusion"},{"key":"10.1186\/s13613-023-01146-5_bb0300","doi-asserted-by":"crossref","first-page":"e02031","DOI":"10.1128\/AAC.02031-18","article-title":"In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models","volume":"63","author":"Nakamura","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1186\/s13613-023-01146-5_bb0305","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ijantimicag.2017.10.008","article-title":"Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model","volume":"51","author":"Ghazi","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1186\/s13613-023-01146-5_bb0310","doi-asserted-by":"crossref","first-page":"e01022","DOI":"10.1128\/AAC.01022-17","article-title":"Efficacy of humanized exposures of cefiderocol (S-649266) against a diverse population of Gram-negative bacteria in a murine thigh infection model","volume":"61","author":"Monogue","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-023-01146-5_bb0315","doi-asserted-by":"crossref","first-page":"e01040","DOI":"10.1128\/AAC.01040-18","article-title":"Efficacy of humanized cefiderocol exposures over 72 hours against a diverse group of Gram-negative isolates in the neutropenic murine thigh infection model","volume":"63","author":"Stainton","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-023-01146-5_bb0320","doi-asserted-by":"crossref","first-page":"dlac047","DOI":"10.1093\/jacamr\/dlac047","article-title":"Assessment of sustained efficacy and resistance emergence under human-simulated exposure of cefiderocol against Acinetobacter baumannii using in vitro chemostat and in vivo murine infection models","volume":"4","author":"Gill","year":"2022","journal-title":"JAC Antimicrob Resist."},{"key":"10.1186\/s13613-023-01146-5_bb0325","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1159\/000487441","article-title":"Humanized exposures of cefiderocol, a siderophore cephalosporin, display sustained in vivo activity against siderophore-resistant Pseudomonas aeruginosa","volume":"101","author":"Ghazi","year":"2018","journal-title":"Pharmacology"},{"key":"10.1186\/s13613-023-01146-5_bb0330","doi-asserted-by":"crossref","first-page":"e00700","DOI":"10.1128\/AAC.00700-17","article-title":"Efficacy of cefiderocol against carbapenem-resistant Gram-negative bacilli in immunocompetent-rat respiratory tract infection models recreating human plasma pharmacokinetics","volume":"61","author":"Matsumoto","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1186\/s13613-023-01146-5_bb0335","article-title":"Synergistic effect of cefiderocol with other antibiotics against PER-producing Acinetobacter baumannii isolates from the multinational SIDERO-WT studies","volume":"7","author":"Yamano","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0340","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jgar.2021.12.017","article-title":"Characterisation of cefiderocol-non-susceptible Acinetobacter baumannii isolates from Taiwan","volume":"28","author":"Yamano","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1186\/s13613-023-01146-5_bb0345","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02646-20","article-title":"In vitro antibacterial activity of cefiderocol against multidrug-resistant Acinetobacter baumannii","volume":"65","author":"Abdul-Mutakabbir","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"10.1186\/s13613-023-01146-5_bb0350","article-title":"In vivo efficacy of human simulated exposures of cefiderocol (FDC) in combination with ceftazidime\/avibactam (CZA) or meropenem (MEM) using in a 72 hour murine thigh infection model","volume":"9","author":"Gill","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0355","doi-asserted-by":"crossref","first-page":"e01381","DOI":"10.1128\/AAC.01381-16","article-title":"Pharmacokinetic\/ pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function","volume":"61","author":"Katsube","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-023-01146-5_bb0360","doi-asserted-by":"crossref","first-page":"e01437","DOI":"10.1128\/AAC.01437-20","article-title":"Population pharmacokinetic and pharmacokinetic\/pharmacodynamic analyses of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia, bloodstream infection\/sepsis, or complicated urinary tract infection","volume":"65","author":"Kawaguchi","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-023-01146-5_bb0365","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0370","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0375","unstructured":"Katsube T, Echols R, Wajima T. Evaluation of cefiderocol exposure based on pharmacokinetic and pharmacokinetic\/pharmacodynamic parameters in critically-ill patients. Presented at: 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID); Virtual congress. 9\u201312 July 2021; Poster 1244."},{"issue":"Suppl. 1","key":"10.1186\/s13613-023-01146-5_bb0380","doi-asserted-by":"crossref","first-page":"S669","DOI":"10.1093\/ofid\/ofaa439.1498","article-title":"Pharmacokinetic\/pharmacodynamic analyses of cefiderocol in critically ill patients","volume":"7","author":"Katsube","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0385","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/jcph.1986","article-title":"Intrapulmonary pharmacokinetic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia and healthy subjects","volume":"62","author":"Kawaguchi","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"10.1186\/s13613-023-01146-5_bb0390","first-page":"52","article-title":"Physical compatibility of cefiderocol with selected intravenous drugs during simulated Y-site administration","volume":"25","author":"Lu","year":"2021","journal-title":"Int J Pharm Compd"},{"key":"10.1186\/s13613-023-01146-5_bb0395","unstructured":"Lynch L, Rathod D, Manrodt R, Chen Z, Fam D, Slover C, et al. Cefiderocol for injection compatibility testing using the MINI-BAG Plus Container System and the VIAL-MATE Adaptor. 2021 ASHP Midyear Congress Virtual Meeting; December 5\u20139, 2021. Poster 1077024."},{"key":"10.1186\/s13613-023-01146-5_bb0400","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0405","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.2147\/IDR.S225553","article-title":"Designing a pathogen-focused study to address the high unmet medical need represented by carbapenem-resistant Gram-negative pathogens\u2014the international, multicenter, randomized, open-label, phase 3 CREDIBLE-CR study","volume":"12","author":"Bassetti","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1186\/s13613-023-01146-5_bb0410","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/phar.2607","article-title":"Treatment of patients with serious infections due to carbapenem-resistant Acinetobacter baumannii: how viable are the current options?","volume":"41","author":"O'Donnell","year":"2021","journal-title":"Pharmacotherapy"},{"key":"10.1186\/s13613-023-01146-5_bb0415","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/14787210.2022.2020099","article-title":"All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies","volume":"20","author":"Lodise","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1186\/s13613-023-01146-5_bb0420","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciac078","article-title":"Cefiderocol for the treatment of infections due to metallo-beta-lactamase-producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 randomized studies","author":"Timsit","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0425","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01100-22","article-title":"Evidence for efficacy of cefiderocol against OXA-48-containing isolates from the APEKS-NP and CREDIBLE-CR trials","volume":"66","author":"Longshaw","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-023-01146-5_bb0430","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10096-021-04399-9","article-title":"Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP study","volume":"41","author":"Skaar","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0435","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s40121-022-00598-9","article-title":"Outcomes with cefiderocol treatment in patients with bacteraemia enrolled into prospective Phase 2 and Phase 3 randomised clinical studies","volume":"11","author":"Paterson","year":"2022","journal-title":"Infect Dis Ther"},{"issue":"Suppl 1","key":"10.1186\/s13613-023-01146-5_bb0440","doi-asserted-by":"crossref","first-page":"S661","DOI":"10.1093\/ofid\/ofaa439.1475","article-title":"Safety profile of the novel siderophore cephalosporin cefiderocol in randomized phase 2 and phase 3 clinical studies of serious Gram-negative infections","volume":"7","author":"Matsunaga","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl. 1","key":"10.1186\/s13613-023-01146-5_bb0445","first-page":"P124","article-title":"Effects of iron supplementation on the efficacy of cefiderocol in patients with carbapenem-resistant infections in the pathogen-focused CREDIBLE-CR study","volume":"25","author":"Longshaw","year":"2021","journal-title":"Crit Care"},{"issue":"Suppl. 1","key":"10.1186\/s13613-023-01146-5_bb0450","first-page":"P123","article-title":"Impact of cefiderocol treatment on iron homeostasis and anaemia in critically ill patients with carbapenem-resistant infections in the CREDIBLE-CR study","volume":"25","author":"Longshaw","year":"2021","journal-title":"Crit Care"},{"key":"10.1186\/s13613-023-01146-5_bb0455","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol-compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-023-01146-5_bb0460","doi-asserted-by":"crossref","first-page":"dlab174","DOI":"10.1093\/jacamr\/dlab174","article-title":"Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study","volume":"3","author":"Pascale","year":"2021","journal-title":"JAC Antimicrob Resist."},{"key":"10.1186\/s13613-023-01146-5_bb0465","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/antibiotics11010003","article-title":"Cefiderocol for severe carbapenem-resistant A. baumannii pneumonia: towards the comprehension of its place in therapy","volume":"11","author":"Rando","year":"2021","journal-title":"Antibiotics (Basel)."},{"key":"10.1186\/s13613-023-01146-5_bb0470","doi-asserted-by":"crossref","first-page":"dlab188","DOI":"10.1093\/jacamr\/dlab188","article-title":"Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections","volume":"3","author":"Meschiari","year":"2021","journal-title":"JAC Antimicrob Resist."},{"key":"10.1186\/s13613-023-01146-5_bb0475","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jgar.2021.10.014","volume":"27","author":"Gatti","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1186\/s13613-023-01146-5_bb0480","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jgar.2021.09.005","article-title":"Successful prolonged cefiderocol treatment of a chronic left pleural empyema caused by Pseudomonas aeruginosa in a patient affected by COVID-19: a case report","volume":"27","author":"Borghesi","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1186\/s13613-023-01146-5_bb0485","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00924-21","article-title":"Extensively drug-resistant Acinetobacter baumannii nosocomial pneumonia successfully treated with a novel antibiotic combination","volume":"65","author":"Zaidan","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-023-01146-5_bb0490","doi-asserted-by":"crossref","first-page":"ofab252","DOI":"10.1093\/ofid\/ofab252","article-title":"Cefiderocol pharmacokinetics in a patient receiving continuous venovenous hemodiafiltration","volume":"8","author":"Kobic","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"10.1186\/s13613-023-01146-5_bb0495","doi-asserted-by":"crossref","first-page":"ofac484","DOI":"10.1093\/ofid\/ofac484","article-title":"Pharmacokinetic analysis and in vitro synergy evaluation of cefiderocol, sulbactam, and tigecycline in an extensively drug-resistant Acinetobacter baumannii pneumonia patient receiving continuous venovenous hemodiafiltration","volume":"9","author":"Kobic","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0500","article-title":"Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections","author":"Gavaghan","year":"2022","journal-title":"Infection"},{"key":"10.1186\/s13613-023-01146-5_bb0505","doi-asserted-by":"crossref","unstructured":"Bleibtreu A, Dortet L, Bonnin RA, Wyplosz B, Sacleux SC, Mihaila L, et al.; The Cefiderocol French Study Group OBO. Susceptibility testing is key for the success of cefiderocol treatment: a retrospective cohort study. Microorganisms. 2021;9:282.","DOI":"10.3390\/microorganisms9020282"},{"key":"10.1186\/s13613-023-01146-5_bb0510","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.medmal.2020.10.022","article-title":"Compassionate use of cefiderocol in a pancreatic abscess and emergence of resistance","volume":"51","author":"Grande Perez","year":"2021","journal-title":"Infect Dis Now"},{"key":"10.1186\/s13613-023-01146-5_bb0515","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jgar.2020.09.019","article-title":"Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii","volume":"23","author":"Oliva","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1186\/s13613-023-01146-5_bb0520","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/cid\/ciaa1410","article-title":"Cefiderocol as rescue therapy for Acinetobacter baumannii and other Carbapenem-resistant Gram-negative infections in intensive care unit patients","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0525","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1002\/ppul.24945","article-title":"Combining bacteriophages with cefiderocol and meropenem\/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient","volume":"55","author":"Gainey","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"10.1186\/s13613-023-01146-5_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.idcr.2020.e00863","article-title":"Cefiderocol for treatment of an empyema due to extensively drug-resistant Pseudomonas aeruginosa: clinical observations and susceptibility testing considerations","volume":"21","author":"Kufel","year":"2020","journal-title":"IDCases"},{"key":"10.1186\/s13613-023-01146-5_bb0535","doi-asserted-by":"crossref","first-page":"ofaa185","DOI":"10.1093\/ofid\/ofaa185","article-title":"Cefiderocol for extensively drug-resistant Gram-negative bacterial infections: real-world experience from a case series and review of the literature","volume":"7","author":"Zingg","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0540","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/phar.2334","article-title":"Compassionate use of cefiderocol in the treatment of an intraabdominal infection due to multidrug-resistant Pseudomonas aeruginosa: a case report","volume":"39","author":"Stevens","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1186\/s13613-023-01146-5_bb0545","doi-asserted-by":"crossref","first-page":"e00948","DOI":"10.1128\/AAC.00948-19","article-title":"Coinfections of two strains of NDM-1- and OXA-232-coproducing Klebsiella pneumoniae in a kidney transplant patient","volume":"64","author":"Contreras","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-023-01146-5_bb0550","doi-asserted-by":"crossref","unstructured":"Trecarichi EM, Quirino A, Scaglione V, Longhini F, Garofalo E, Bruni A, et al.; IMAGES Group. Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report. J Antimicrob Chemother. 2019;74:3399\u2013401.","DOI":"10.1093\/jac\/dkz318"},{"key":"10.1186\/s13613-023-01146-5_bb0555","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/cid\/ciy963","article-title":"Compassionate use of cefiderocol as adjunctive treatment of native aortic valve endocarditis due to extremely drug-resistant Pseudomonas aeruginosa","volume":"68","author":"Edgeworth","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0560","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3390\/antibiotics10060652","article-title":"Cefiderocol-based combination therapy for \"difficult-to-treat\" Gram-negative severe infections: real-life case series and future perspectives","volume":"10","author":"Bavaro","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1186\/s13613-023-01146-5_bb0565","first-page":"1","article-title":"Real-life data on the effectiveness and safety of cefiderocol in severely infected patients: a case series","volume":"21","author":"Fendian","year":"2023","journal-title":"Infect Dis Ther"},{"key":"10.1186\/s13613-023-01146-5_bb0570","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.3390\/antibiotics11121830","article-title":"Pharmacokinetic of cefiderocol in critically ill patients receiving renal replacement therapy: a case series","volume":"11","author":"Mornese Pinna","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1186\/s13613-023-01146-5_bb0575","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.3390\/antibiotics11121686","article-title":"Successful treatment of aortic endocarditis by Achromobacter xylosoxidans with cefiderocol combination therapy in a non-Hodgkin lymphoma patient: case report and literature review","volume":"11","author":"La Bella","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1186\/s13613-023-01146-5_bb0580","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.cmi.2022.11.005","article-title":"Real-world clinical outcome of cefiderocol for treatment of multidrug-resistant non-fermenting, gram negative bacilli infections: a case series","volume":"29","author":"Hoellinger","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 2","key":"10.1186\/s13613-023-01146-5_bb0585","article-title":"Outcomes using cefiderocol for the treatment of Acinetobacter baumannii infections from the PROVE (real-world evidence) study","volume":"9","author":"Marcella","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl 2","key":"10.1186\/s13613-023-01146-5_bb0590","article-title":"Real-world experience of cefiderocol with Pseudomonas aeruginosa in the PROVE (retrospective cefiderocol chart review) study","volume":"9","author":"Marcella","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl 2","key":"10.1186\/s13613-023-01146-5_bb0595","article-title":"Systematic review of the early use experience of cefiderocol in real world practice","volume":"9","author":"Viale","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0600","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/cid\/ciab511","article-title":"Rapid development of cefiderocol resistance in carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the catecholate siderophore receptor cirA","volume":"74","author":"Klein","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0605","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/cid\/ciab888","article-title":"Progressive development of cefiderocol resistance in Escherichia coli during therapy is associated with an increase in blaNDM-5 copy number and gene expression","volume":"75","author":"Simner","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0610","article-title":"Evolution and transmission of cefiderocol-resistant Acinetobacter baumanniiduring an outbreak in the burn intensive care unit","author":"Smoke","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0615","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3390\/antibiotics11060723","article-title":"Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance","volume":"11","author":"Karakonstantis","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1186\/s13613-023-01146-5_bb0620","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/mdr.2021.0095","article-title":"Defining baseline mechanisms of cefiderocol resistance in the Enterobacterales","volume":"28","author":"Simner","year":"2022","journal-title":"Microb Drug Resist"},{"key":"10.1186\/s13613-023-01146-5_bb0625","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.01779-21","article-title":"In vitro evolution of cefiderocol resistance in an NDM-producing Klebsiella pneumoniaedue to functional loss of cirA","author":"McElheny","year":"2021","journal-title":"Microbiol Spectr."},{"key":"10.1186\/s13613-023-01146-5_bb0630","doi-asserted-by":"crossref","first-page":"2200795","DOI":"10.2807\/1560-7917.ES.2022.27.43.2200795","article-title":"Nosocomial outbreak by NDM-1-producing Klebsiella pneumoniae highly resistant to cefiderocol, Florence, Italy, August 2021 to June 2022","volume":"27","author":"Coppi","year":"2022","journal-title":"Euro Surveill"},{"key":"10.1186\/s13613-023-01146-5_bb0635","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1089\/mdr.2021.0180","article-title":"Mechanisms of reduced susceptibility to cefiderocol among isolates from the CREDIBLE-CR and APEKS-NP clinical trials","volume":"28","author":"Nordmann","year":"2022","journal-title":"Microb Drug Resist"},{"issue":"4","key":"10.1186\/s13613-023-01146-5_bb0640","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1093\/jac\/dkad004","article-title":"Rapid selection of a cefiderocol-resistant Escherichia coli producing NDM-5 associated with a single amino acid substitution in the CirA siderophore receptor","volume":"78","author":"Jousset","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1186\/s13613-023-01146-5_bb0645","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01724-22","article-title":"In vitro activity of cefiderocol against extensively drug-resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019","volume":"10","author":"Karlowsky","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1186\/s13613-023-01146-5_bb0650","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1186\/s13613-023-01146-5_bb0655","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/cid\/ciac268","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0660","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America guidance on the treatment of ampc \u03b2-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0665","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/14787210.2021.1976145","article-title":"An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of infection-related ventilator associated complications (IVACs) caused by Enterobacterales in critically ill adult patients","volume":"20","author":"Gatti","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1186\/s13613-023-01146-5_bb0670","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.2147\/IDR.S314241","article-title":"An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of BSIs, cUTIs, and cIAIs caused by Enterobacterales in critically ill adult patients","volume":"14","author":"Gatti","year":"2021","journal-title":"Infect Drug Resist"},{"key":"10.1186\/s13613-023-01146-5_bb0675","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/antibiotics11010033","article-title":"An evidence-based multidisciplinary approach focused on creating algorithms for targeted therapy of infection-related ventilator-associated complications (IVACs) caused by Pseudomonas aeruginosa and Acinetobacter baumannii in critically ill adult patients","volume":"11","author":"Gatti","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1186\/s13613-023-01146-5_bb0680","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.arcmed.2021.09.002","article-title":"Management of infections caused by multidrug-resistant Gram-negative pathogens: recent advances and future directions","volume":"52","author":"Bassetti","year":"2021","journal-title":"Arch Med Res"},{"key":"10.1186\/s13613-023-01146-5_bb0685","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/QCO.0000000000000596","article-title":"An overview of guidelines for the management of hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria","volume":"32","author":"Cill\u00f3niz","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0690","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s13054-020-03091-2","article-title":"Update of the treatment of nosocomial pneumonia in the ICU","volume":"24","author":"Zaragoza","year":"2020","journal-title":"Crit Care"},{"key":"10.1186\/s13613-023-01146-5_bb0695","unstructured":"Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:e61\u2013e111. Erratum in: Clin Infect Dis. 2017;64:1298. Erratum in: Clin Infect Dis. 2017;65:1435."},{"key":"10.1186\/s13613-023-01146-5_bb0700","doi-asserted-by":"crossref","unstructured":"Bougl\u00e9 A, Tuffet S, Federici L, Leone M, Monsel A, Dessalle T, et al; iDIAPASON Trial Investigators. Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial. Intensive Care Med. 2022;48:841\u20139.","DOI":"10.1007\/s00134-022-06690-5"},{"key":"10.1186\/s13613-023-01146-5_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101880","article-title":"Comparison of a short versus long-course antibiotic therapy for ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials","volume":"58","author":"Daghmouri","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1186\/s13613-023-01146-5_bb0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106811","article-title":"Impact of a real-time diagnostic and antimicrobial stewardship workflow on time-to-appropriate therapy for infections caused by multidrug-resistant Gram-negative organisms","author":"McCrink","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1186\/s13613-023-01146-5_bb0715","doi-asserted-by":"crossref","unstructured":"Abdul-Aziz MH, Alffenaar JC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al.; Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic\/pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med. 2020;46:1127\u201353.","DOI":"10.1007\/s00134-020-06050-1"},{"key":"10.1186\/s13613-023-01146-5_bb0720","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1186\/s13054-020-03272-z","article-title":"Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT)","volume":"24","author":"Abdulla","year":"2020","journal-title":"Crit Care"},{"key":"10.1186\/s13613-023-01146-5_bb0725","article-title":"Setting the beta-lactam therapeutic range for critically ill patients: is there a floor or even a ceiling?","volume":"3","author":"Barreto","year":"2021","journal-title":"Crit Care Explor"},{"key":"10.1186\/s13613-023-01146-5_bb0730","article-title":"\u03b2-lactam therapeutic drug monitoring in critically ill patients: weighing the challenges and opportunities to assess clinical value","volume":"4","author":"Dilworth","year":"2022","journal-title":"Crit Care Explor"},{"key":"10.1186\/s13613-023-01146-5_bb0735","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1186\/s13063-021-05870-w","volume":"22","author":"Wright","year":"2021","journal-title":"Trials"},{"issue":"Suppl. 1","key":"10.1186\/s13613-023-01146-5_bb0740","doi-asserted-by":"crossref","first-page":"S621","DOI":"10.1093\/ofid\/ofab466.1252","article-title":"In vitro and in vivo antibacterial activity of cefiderocol against Burkholderia spp","volume":"8","author":"Oota","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1186\/s13613-023-01146-5_bb0745","unstructured":"Avycaz (ceftazidime-avibactam for injection for intravenous use). Prescribing Information. Allergan USA, Inc., Madison, NJ 07940, USA. 2020."},{"key":"10.1186\/s13613-023-01146-5_bb0750","unstructured":"Zavicefta. Ceftazidime-avibactam (2 g\/0.5g powder for concentrate for solution for infusion). Summary of Product Characteristics. Pfizer Ireland Pharmaceuticals Operations Support Group. Ringaskiddy, County Cork, Ireland. 2021."},{"key":"10.1186\/s13613-023-01146-5_bb0755","unstructured":"Zerbaxa. Ceftolozane-tazobactam for injection for intravenous use. Prescribing Information. Merck & Co., Inc. Whitehouse Stations, NJ 08889, USA. 2020."},{"key":"10.1186\/s13613-023-01146-5_bb0760","unstructured":"Zerbaxa. Ceftolozane-tazobactam (1 g\/0.5g powder for solution for infusion). Summary of Product Characteristics. Merck Sharp & Dohme B.V. Waarderweg 39, 2031 BN Haarlem, The Netherlands. 2020."},{"key":"10.1186\/s13613-023-01146-5_bb0765","unstructured":"Recarbrio (imipenem-cilastatin-relebactam for injection for intravenous use). Prescribing Information. Merck & Co., Inc. Whitehouse Station, NJ 08889, USA. 2020."},{"key":"10.1186\/s13613-023-01146-5_bb0770","unstructured":"Recarbrio. Imipenem-cilastatin-relebactam (500 mg\/500 mg\/250 mg powder for solution for infusion). Summary of Product Characteristics. Merck Sharp & Dohme B.V. Waarderweg 39, 2031 BN Haarlem, The Netherlands. 2020."},{"key":"10.1186\/s13613-023-01146-5_bb0775","unstructured":"Vabomere (meropenem and vaborbactam for injection, for intravenous use). Prescribing Information. Melinta Therapeutics, LLC, Lincolnshire, IL 60069, USA. 2020."},{"key":"10.1186\/s13613-023-01146-5_bb0780","unstructured":"Vaborem (meropenem\/vaborbactam 1 g\/1 g powder for concentrate for solution for infusion). Summary of Product Characteristics. Menarini International Operations Luxembourg S.A.; 1 Avenue de la Gare, L-1611, Luxembourg. 2021."}],"container-title":["Annals of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-023-01146-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13613-023-01146-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025004704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025004704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-023-01146-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:37:16Z","timestamp":1776670636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2110582025004704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":155,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"alternative-id":["S2110582025004704"],"URL":"https:\/\/doi.org\/10.1186\/s13613-023-01146-5","relation":{},"ISSN":["2110-5820"],"issn-type":[{"value":"2110-5820","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence","name":"articletitle","label":"Article Title"},{"value":"Annals of Intensive Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1186\/s13613-023-01146-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 The Author(s) 2023. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}],"article-number":"52"}}